What is CBG?
CBG* has shown promising results in the many treatments. However, since CBG appears as a relatively low concentration intermediate in the plant, therapeutic administration of CBG oil could be limited by the low amount of compound obtained from plant extraction.
Fortunately, recent breeding work has yielded cannabis chemotypes lacking in downstream enzymes that express 100% of their phytocannabinoid content as CBG.42 After 9 years of hard work and breeding programs at endoca we have created CBG oil and pure 99% CBG isolate. Albeit additional studies are needed in order to confirm and enlarge the wide variety of therapeutic applications of CBG oil.
*We are currently not offering CBG for wholesale
- DEVANE, W. et al. Determination Rat Brain and Characterization of a Cannabinoid Receptor in Rat Brain. Mol. Pharmacol. 34, 605–613 (1988).
- Devane, W. a et al. Isolation and Structure of Brain Constituent that binds to the Cannabinoid Receptor. Science (80-. ). 258, 1946–1949 (1992).
- Mechoulam, R. et al. Identification Present in Canine Gut , That Binds To Cannabinoid Receptors. 50, 83–90 (1995).
- Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fat. Acids 66, 101–121 (2002).
- Russo, E. B. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis Cannabinoid Res. 1, 154–165 (2016).
- Mahmoud, A. Marijuana and the Cannabinoids. (Humana Press, 2007).
- Russo, E. B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344–1364 (2011).
- Turner, S. E., Williams, C. M., Iversen, L. & Whalley, B. J. Molecular Pharmacology of Phytocannabinoids. (2017). doi:10.1007/978-3-319-45541-9
- Gaoni, Y. & Mechoulam, R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc 86, 1646–1647 (1964).
- Mbvundula, E. C., Rainsford, K. D. & Bunning, R. A. Cannabinoids in pain and inflammation. Inflammopharmacology 12, 99–114 (2004).
- Iseger, T. A. & Bossong, M. G. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res. 162, 153–161 (2015).
- Devinsky, O. et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55, 791–802 (2014).
- Elsohly, M. A., Radwan, M. M., Gul, W., Chandra, S. & Galal, A. Phytocannabinoids. 103, (2017).
- Pertwee, R. G. Endocannabinoids. (Springer US, 2015).
- Leo, A., Russo, E. & Elia, M. Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol. Res. 107, 85–92 (2016).
- Whiting, P. F. et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jama 313, 2456–2473 (2015).
- Wierzbicki, A. S. Rimonabant: Endocannabinoid inhibition for the metabolic syndrome. Int. J. Clin. Pract. 60, 1697–1706 (2006).
- Tai, S. & Fantegrossi, W. E. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Curr Addict Rep. 1, 129–136 (2014).
- Gurney, S., Scott, K., Kacinko, S., Presley, B. & Logan, B. Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. Forensic Sci Rev. 26, 53–78 (2014).
- Moreira, F. A. & Crippa, J. A. S. The psychiatric side-effects of rimonabant. Rev. Bras. Psiquiatr. 31, 145–53 (2009).
- Rosenthal, E. & Kubby, S. Why Marijushould be legal. (Running press, London, 1996).
- Appendino, G. et al. Antibacterial Cannabinoids from Cannabis sativa?: A Structure - Activity Study. J. Nat. Prod. 71, 1427–1430 (2008).
- Fellermeier, M. & Zenk, M. H. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Lett. 427, 283–285 (1998).
- Zirpel, B., Stehle, F. & Kayser, O. Production of???9-tetrahydrocannabinolic acid from cannabigerolic acid by whole cells of Pichia (Komagataella) pastoris expressing???9-tetrahydrocannabinolic acid synthase from Cannabis sativa l. Biotechnol. Lett. 37, 1869–1875 (2015).
- Gauson, L. A. et al. Cannabigerol behaves as a partial agonist at both CB1 and CB2 receptors. Symp. Cannabinoids 26 June-1 July 206 (2007).
- Banebjee, S. P., Mechoulam, S. & Snydeji, H. Cannabinoids: influence in neurotransmitter uptake Influence in Rat brain synaptosoms. J. Pharmacol. Exp. Ther. 194, 74–81 (1975).
- Kargmanss, S., Prasitn, P. & Evans, J. F. Translocation of HL-60 Cell 5-Lipoxygenase. (1991).
- Milman, G. et al. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. PNAS 103, 2428–2433 (2006).
- Evelyn, A., Formukong, A., Evans, T. & Evans, F. J. Inhibition of the cataleptic effect of tetrahydrobannabinol by other constituents of Cannabis Sativa L. Jo. Pharm. Pharmacol. 40, 132–134 (1985).
- Cascio, M. G., Gauson, L. A., Stevenson, L. A., Ross, R. A. & Pertwee, R. G. Evidence that the plant cannabinoid cannabigerol is a highly potent ? 2-adrenoceptor agonist and moderately potent 5HT 1A receptor antagonist. Br. J. Pharmacol. 159, 129–141 (2010).
- Wilkinson, J. D. & Williamson, E. M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J. Dermatol. Sci. 45, 87–92 (2007).
- Ortar, G. et al. (-)-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. Bioorganic Med. Chem. Lett. 20, 2729–2732 (2010).
- Mukerji, G., Yiangou, Y., Agarwal, S. K. & Anand, P. Transient receptor potential vanilloid receptor subtype 1 in painful bladder syndrome and its correlation with pain. J. Urol. 176, 797–801 (2006).
- SH1, B. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res. 21, 353–356 (1998).
- Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318, 1375–1387 (2006).
- Eisohly, H. N., Turner, C. E., Clark, A. M. & Eisohly, M. A. Synthesis and Anti-Microbial Activities of Certain Cannabichromene and Cannabigerol Related-Compounds. J. Pharm. Sci. 71, 1319–1323 (1982).
- De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163, 1479–1494 (2011).
- DM, V. et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol. 42, 111–117 (1998).
- De-oliveira, A. C. A. X., Ribeiro-pinto, L. F., Otto, S. S. & Gonc, A. Induction of liver monooxygenases by i -myrcene. Toxicology 124, 135–140 (1997).
- L, R. et al. Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain. Mini Rev Med Chem. 16, 721–728 (2016).
- D, Y., L, M., JP, C. & J., M.-C. Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis. Mycopathologia 148, 79–82 (1999).
- De Meijer, E. P. M. & Hammond, K. M. The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants. Euphytica 145, 189–198 (2005).